Aclaris Therapeutics, Inc.
$4.25
▲
1.45%
2026-04-21 05:04:00
www.aclaristx.com
NMS: ACRS
Explore Aclaris Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$512.53 M
Current Price
$4.25
52W High / Low
$4.89 / $1.08
Stock P/E
—
Book Value
$0.85
Dividend Yield
—
ROCE
-53.3%
ROE
-50.2%
Face Value
—
EPS
$-0.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
69
Beta
0.68
Debt / Equity
2.05
Current Ratio
3.36
Quick Ratio
3.36
Forward P/E
-5.39
Price / Sales
62.51
Enterprise Value
$398.57 M
EV / EBITDA
-5.38
EV / Revenue
50.93
Rating
Strong Buy
Target Price
$8.29
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 2. | Ensysce Biosciences, Inc. | $0.48 | — | $4.49 M | — | -355% | -3.25% | $4.85 / $0.31 | $0.7 |
| 3. | Design Therapeutics, Inc. | $13.16 | — | $809.14 M | — | -37.28% | -30.7% | $13.5 / $3.1 | $3.52 |
| 4. | Oncolytics Biotech Inc. | $1.11 | — | $163.05 M | — | -1939.57% | 11480.64% | $1.85 / $0.45 | $0 |
| 5. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 6. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 7. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.29 M | 3.3 M | 1.78 M | 1.46 M | 9.21 M | — |
| Operating Profit | -21.03 M | -16.33 M | -15.95 M | -16.95 M | -12.16 M | — |
| Net Profit | -19.8 M | -14.61 M | -15.43 M | -15.09 M | -96.55 M | — |
| EPS in Rs | -0.16 | -0.12 | -0.13 | -0.12 | -0.8 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.83 M | 18.72 M | 31.25 M | 29.75 M |
| Operating Profit | -70.26 M | -50.61 M | -116.31 M | -85.15 M |
| Net Profit | -64.92 M | -132.06 M | -88.48 M | -86.91 M |
| EPS in Rs | -0.54 | -1.09 | -0.73 | -0.72 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 160.46 M | 220.33 M | 197.41 M | 254.6 M |
| Total Liabilities | 57.38 M | 64.77 M | 40.23 M | 56.98 M |
| Equity | 103.08 M | 155.55 M | 157.18 M | 197.62 M |
| Current Assets | 96.32 M | 125.95 M | 128.86 M | 231.55 M |
| Current Liabilities | 28.64 M | 31.6 M | 30.95 M | 21.94 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -47.11 M | -20.07 M | -78.33 M | -67.57 M |
| Investing CF | 48.37 M | -69.77 M | 46.22 M | 12.63 M |
| Financing CF | -5.86 M | 74.54 M | 26.71 M | 72.87 M |
| Free CF | -47.22 M | -56.01 M | -79.63 M | -68.17 M |
| Capex | -0.11 M | -35.93 M | -1.31 M | -0.6 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -40.09% | 5.03% | — | — |
| Earnings Growth % | -49.26% | -1.81% | — | — |
| Profit Margin % | -705.48% | -283.15% | -292.11% | — |
| Operating Margin % | -270.37% | -372.22% | -286.21% | — |
| Gross Margin % | 17.43% | 42.14% | 59.8% | — |
| EBITDA Margin % | -266.06% | -369.46% | -283.53% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.